Format

Send to

Choose Destination
Nat Rev Drug Discov. 2017 Oct;16(10):736. doi: 10.1038/nrd.2017.153. Epub 2017 Sep 22.

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem.

Author information

1
Critical Path Institute, Tucson, Arizona, USA.
2
Biogen, Cambridge, Massachusetts, USA.
3
Food and Drug Administration, Bethesda, Maryland, USA.
4
TEVA, Cambridge, Massachusetts, USA. Present address: Massachusetts General Hospital, Harvard, Boston, Massachusetts, USA.
5
IXICO, London, UK.
6
Loma Linda University, Loma Linda, California, USA.
7
Alzheimer's Drug Discovery Foundation, New York, New York, USA. Present address: American Epilepsy Association, Chicago, Illinois, USA.
8
Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA. Present address: TEVA, Malvern, Pennsylvania, USA.
9
UsAgainstAlzheimer's, Washington, DC, USA.
10
Boston University, Boston, Massachusetts, USA.
11
Pfizer, Boston, Massachusetts, USA.
12
AbbVie, North Chicago, Illinois, USA.
13
CHDI Foundation, Princeton, New Jersey, USA.
14
Pfizer, Boston, Massachusetts, USA. Present address: Homology Medicines, Boston, Massachusetts, USA.
15
Eli Lilly &Company, Indianapolis, Indianapolis, USA.
16
Oregon Health &Science University, Portland, Oregon, USA.
PMID:
28935908
DOI:
10.1038/nrd.2017.153

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center